{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T20:22:36Z","timestamp":1751055756845,"version":"3.40.5"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The use of amyloid-PET in dementia workup is upcoming. At the same time, amyloid-PET is costly and limitedly available. While the appropriate use criteria (AUC) aim for optimal use of amyloid-PET, their limited sensitivity hinders the translation to clinical practice. Therefore, there is a need for tools that guide selection of patients for whom amyloid-PET has the most clinical utility. We aimed to develop a computerized decision support approach to select patients for amyloid-PET.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We included 286 subjects (135 controls, 108 Alzheimer\u2019s disease dementia, 33 frontotemporal lobe dementia, and 10 vascular dementia) from the Amsterdam Dementia Cohort, with available neuropsychology, APOE, MRI and [<jats:sup>18<\/jats:sup>F]florbetaben amyloid-PET. In our computerized decision support approach, using supervised machine learning based on the DSI classifier, we first classified the subjects using only neuropsychology, APOE, and quantified MRI. Then, for subjects with uncertain classification (probability of correct class (PCC) &lt; 0.75) we enriched classification by adding (hypothetical) amyloid positive (AD-like) and negative (normal) PET visual read results and assessed whether the diagnosis became more certain in at least one scenario (PPC\u22650.75). If this was the case, the actual visual read result was used in the final classification. We compared the proportion of PET scans and patients diagnosed with sufficient certainty in the computerized approach with three scenarios: 1) without amyloid-PET, 2) amyloid-PET according to the AUC, and 3) amyloid-PET for all patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The computerized approach advised PET in n = 60(21%) patients, leading to a diagnosis with sufficient certainty in n = 188(66%) patients. This approach was more efficient than the other three scenarios: 1) without amyloid-PET, diagnostic classification was obtained in n = 155(54%), 2) applying the AUC resulted in amyloid-PET in n = 113(40%) and diagnostic classification in n = 156(55%), and 3) performing amyloid-PET in all resulted in diagnostic classification in n = 154(54%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our computerized data-driven approach selected 21% of memory clinic patients for amyloid-PET, without compromising diagnostic performance. Our work contributes to a cost-effective implementation and could support clinicians in making a balanced decision in ordering additional amyloid PET during the dementia workup.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0303111","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:33:01Z","timestamp":1716226381000},"page":"e0303111","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Computerized decision support is an effective approach to select memory clinic patients for amyloid-PET"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6476-4670","authenticated-orcid":true,"given":"Hanneke F. M.","family":"Rhodius-Meester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid S.","family":"van Maurik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyduine E.","family":"Collij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0669-2584","authenticated-orcid":true,"given":"Aniek M.","family":"van Gils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha","family":"Koikkalainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Tolonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolande A. L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Berkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-4233","authenticated-orcid":true,"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyrki","family":"L\u00f6tj\u00f6nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"pone.0303111.ref001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","article-title":"Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"52","author":"K Chiotis","year":"2017","journal-title":"Neurobiol Aging"},{"issue":"8","key":"pone.0303111.ref002","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers","volume":"16","author":"GB Frisoni","year":"2017","journal-title":"The Lancet Neurology"},{"issue":"Suppl 1","key":"pone.0303111.ref003","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.neurobiolaging.2011.09.006","article-title":"Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia","volume":"32","author":"WE Klunk","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"13","key":"pone.0303111.ref004","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia","volume":"321","author":"GD Rabinovici","year":"2019","journal-title":"Jama"},{"issue":"9","key":"pone.0303111.ref005","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","article-title":"Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project","volume":"75","author":"A de Wilde","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"pone.0303111.ref006","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","article-title":"Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia","volume":"9","author":"MD Zwan","year":"2017","journal-title":"Alzheimer\u2019s research & therapy"},{"issue":"3","key":"pone.0303111.ref007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","article-title":"AMYPAD Diagnostic and Patient Management Study: Rationale and design","volume":"15","author":"GB Frisoni","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"6","key":"pone.0303111.ref008","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaneurol.2023.0997","article-title":"Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial","volume":"80","author":"D Altomare","year":"2023","journal-title":"JAMA Neurol"},{"issue":"21","key":"pone.0303111.ref009","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2018.17163","article-title":"Clinical Decision Support in the Era of Artificial Intelligence","volume":"320","author":"EH Shortliffe","year":"2018","journal-title":"Jama"},{"issue":"11","key":"pone.0303111.ref010","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias","volume":"19","author":"G Ch\u00e9telat","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"pone.0303111.ref011","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020315","article-title":"The Road to Personalized Medicine in Alzheimer\u2019s Disease: The Use of Artificial Intelligence","volume":"10","author":"A Silva-Sp\u00ednola","year":"2022","journal-title":"Biomedicines"},{"issue":"8","key":"pone.0303111.ref012","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer\u2019s disease","volume":"2","author":"H Hampel","year":"2022","journal-title":"Nature Aging"},{"issue":"1","key":"pone.0303111.ref013","doi-asserted-by":"crossref","first-page":"e-1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"KA Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"11","key":"pone.0303111.ref014","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jalz.2019.07.003","article-title":"Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project","volume":"15","author":"A de Wilde","year":"2019","journal-title":"Alzheimers Dement"},{"key":"pone.0303111.ref015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.dadm.2016.12.001","article-title":"Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care","volume":"5","author":"LG Apostolova","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"pone.0303111.ref016","first-page":"e12333","article-title":"Amyloid PET ordering practices in a memory disorders clinic","volume":"8","author":"KW Turk","year":"2022","journal-title":"Alzheimer\u2019s & dementia (New York, N Y)"},{"issue":"10","key":"pone.0303111.ref017","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","article-title":"Quantification of amyloid PET for future clinical use: a state-of-the-art review","volume":"49","author":"HG Pemberton","year":"2022","journal-title":"European journal of nuclear medicine and molecular imaging"},{"issue":"1","key":"pone.0303111.ref018","doi-asserted-by":"crossref","first-page":"e0226784","DOI":"10.1371\/journal.pone.0226784","article-title":"Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy","volume":"15","author":"HFM Rhodius-Meester","year":"2020","journal-title":"PloS one"},{"issue":"1","key":"pone.0303111.ref019","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-132306","article-title":"Optimizing patient care and research: the Amsterdam Dementia Cohort","volume":"41","author":"WM van der Flier","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"pone.0303111.ref020","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3233\/JAD-170850","article-title":"Amsterdam Dementia Cohort: Performing Research to Optimize Care","volume":"62","author":"WM van der Flier","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"pone.0303111.ref021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.dadm.2017.01.003","article-title":"Alzheimer\u2019s biomarkers in daily practice (ABIDE) project: Rationale and design","volume":"6","author":"A de Wilde","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3","key":"pone.0303111.ref022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"GM McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"Pt 9","key":"pone.0303111.ref023","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"K Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"11","key":"pone.0303111.ref024","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"ML Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"pone.0303111.ref025","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop","volume":"43","author":"GC Roman","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"pone.0303111.ref026","first-page":"189","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"MF Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"pone.0303111.ref027","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage","volume":"8","author":"R Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"issue":"1","key":"pone.0303111.ref028","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1017\/S1355617706060115","article-title":"Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex","volume":"12","author":"W Van der Elst","year":"2006","journal-title":"J Int Neuropsychol Soc"},{"issue":"12","key":"pone.0303111.ref029","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"JL Cummings","year":"1994","journal-title":"Neurology"},{"issue":"10","key":"pone.0303111.ref030","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","article-title":"Atrophy of medial temporal lobes on MRI in \"probable\" Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates","volume":"55","author":"P Scheltens","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0303111.ref031","article-title":"Automatically computed rating scales from MRI for patients with cognitive disorders","author":"JR Koikkalainen","year":"2019","journal-title":"European radiology"},{"key":"pone.0303111.ref032","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.nicl.2016.02.019","article-title":"Differential diagnosis of neurodegenerative diseases using structural MRI data","volume":"11","author":"J Koikkalainen","year":"2016","journal-title":"Neuroimage Clin"},{"key":"pone.0303111.ref033","doi-asserted-by":"crossref","first-page":"101711","DOI":"10.1016\/j.nicl.2019.101711","article-title":"Detecting frontotemporal dementia syndromes using MRI biomarkers","volume":"22","author":"M Bruun","year":"2019","journal-title":"NeuroImage Clinical"},{"issue":"1","key":"pone.0303111.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"WE Klunk","year":"2015","journal-title":"Alzheimer\u2019s & dementia: the journal of the Alzheimer\u2019s Association"},{"key":"pone.0303111.ref035","article-title":"Quantification of [(18) F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project","author":"LE Collij","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"pone.0303111.ref036","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3233\/JAD-2011-110365","article-title":"A disease state fingerprint for evaluation of Alzheimer\u2019s disease","volume":"27","author":"J Mattila","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"pone.0303111.ref037","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1567205016666190103152425","article-title":"Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study","volume":"16","author":"M Bruun","year":"2019","journal-title":"Current Alzheimer research"},{"issue":"8","key":"pone.0303111.ref038","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jalz.2018.02.022","article-title":"Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET","volume":"14","author":"D Altomare","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"2","key":"pone.0303111.ref039","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuroimage.2004.06.018","article-title":"A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume","volume":"23","author":"RL Buckner","year":"2004","journal-title":"Neuroimage"},{"key":"pone.0303111.ref040","first-page":"77","article-title":"A MATLAB toolbox for classification and visualization of heterogenous multi-scale human data using the Disease State Fingerprint method","volume":"189","author":"L Cluitmans","year":"2013","journal-title":"Stud Health Technol Inform"},{"key":"pone.0303111.ref041","article-title":"Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study","author":"D Altomare","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"pone.0303111.ref042","doi-asserted-by":"crossref","first-page":"e12207","DOI":"10.1002\/dad2.12207","article-title":"Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry","volume":"13","author":"J Albright","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"pone.0303111.ref043","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","article-title":"Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer\u2019s disease: Cross-validation study of practical algorithms","volume":"15","author":"S Palmqvist","year":"2019","journal-title":"Alzheimers Dement"},{"key":"pone.0303111.ref044","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fnagi.2020.00228","article-title":"Detecting Amyloid Positivity in Elderly With Increased Risk of Cognitive Decline","volume":"12","author":"T Pekkala","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"pone.0303111.ref045","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"pone.0303111.ref046","first-page":"398","article-title":"Aducanumab: Appropriate Use Recommendations","volume":"8","author":"J Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"pone.0303111.ref047","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3122\/jabfm.2019.06.180328","article-title":"The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey","volume":"32","author":"J Lam","year":"2019","journal-title":"Journal of the American Board of Family Medicine: JABFM"},{"issue":"12","key":"pone.0303111.ref048","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1002\/alz.13455","article-title":"The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease","volume":"19","author":"K Blennow","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"pone.0303111.ref049","doi-asserted-by":"crossref","first-page":"1175922","DOI":"10.3389\/fneur.2023.1175922","article-title":"Precision medicine in neurodegeneration: the IHI-PROMINENT project","volume":"14","author":"A Tate","year":"2023","journal-title":"Frontiers in neurology"},{"issue":"1","key":"pone.0303111.ref050","first-page":"e12333","article-title":"Development and design of a diagnostic report to support communication in dementia: Co-creation with patients and care partners","volume":"14","author":"AM van Gils","year":"2022","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"pone.0303111.ref051","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fnagi.2018.00111","article-title":"Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier","volume":"10","author":"A Tolonen","year":"2018","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"pone.0303111.ref052","doi-asserted-by":"crossref","first-page":"e12379","DOI":"10.1002\/dad2.12379","article-title":"Optimizing cCOG, a Web-based tool, to detect dementia with Lewy Bodies","volume":"14","author":"AM van Gils","year":"2022","journal-title":"Alzheimers Dement (Amst)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:33:33Z","timestamp":1716226413000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303111"}},"subtitle":[],"editor":[{"given":"Wataru","family":"Araki","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0303111","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}